11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 7 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 4 | 1 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $143.91, a high estimate of $247.00, and a low estimate of $90.00. This current average has decreased by 10.97% from the previous average price target of $161.64.
Decoding Analyst Ratings: A Detailed Look
A clear picture of Illumina's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Catherine Ramsey | Baird | Lowers | Neutral | $90.00 | $127.00 |
| Patrick Donnelly | Citigroup | Lowers | Neutral | $90.00 | $130.00 |
| Tejas Savant | Morgan Stanley | Lowers | Equal-Weight | $136.00 | $150.00 |
| David Westenberg | Piper Sandler | Raises | Overweight | $190.00 | $185.00 |
| Luke Sergott | Barclays | Lowers | Underweight | $100.00 | $130.00 |
| Conor McNamara | RBC Capital | Lowers | Outperform | $247.00 | $250.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Hold | $135.00 | $145.00 |
| Subbu Nambi | Guggenheim | Lowers | Buy | $150.00 | $170.00 |
| Luke Sergott | Barclays | Lowers | Equal-Weight | $130.00 | $145.00 |
| Tejas Savant | Morgan Stanley | Lowers | Equal-Weight | $150.00 | $156.00 |
| Patrick Donnelly | Citigroup | Lowers | Neutral | $165.00 | $190.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Illumina compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Illumina's stock. This examination reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Illumina's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Illumina analyst ratings.
Discovering Illumina: A Closer Look
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Financial Insights: Illumina
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Illumina's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.6% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Illumina's net margin excels beyond industry benchmarks, reaching 16.94%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Illumina's ROE excels beyond industry benchmarks, reaching 8.31%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Illumina's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.04% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Illumina's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
